Although this work may not have confirmed a clear role for IL-17A, it became evident that in response to ICI treatment, patients that develop ICI-Pneumonitis recruit increased numbers of inflammatory cells to the lungs, while immunoregulatory populations decreased in number and potency. Here, IL17A is linked to pneumonitis.